In contrast to breast and renal clear cell cancers where TGFBR3 and ENG both impacted the effect of INHA on survival, TGFBR3 levels did not change INHA’s impact on p53 mutated serous ovarian cancers (Table 1). This evidence concerns the gene TGFBR3 and ovarian serous adenocarcinoma.